It’s 2021 and regular THC isn’t going to cut it for the budding weed industry. Neither will CBD. Instead, a host of startups are betting that weed consumers will be clamoring for something that nature alone can’t provide.
In Berkeley, California, the startup Demetrix, is preparing to manufacture “metric tons” of...
David Schaffer, Hertz Fellow, gene therapy researcher, and The Hubbard Howe Jr. Distinguished Professor of Biochemical Engineering at UC Berkeley says he “plays Darwin” in his Berkeley lab, using high throughput genetic sequencing technology to test over a billion genetic samples for the desired biological activity.
Guided by CRISPR pioneer Jennifer Doudna, a formidable entrepreneur in her own right, C&EN profiled 15 women working in the Chemical industry in academics and startups in C&EN's 2020 Trailblazers. Four of them are affiliated with UC Berkeley's College of Chemistry. They have collectively launched more than 30 start-ups aimed at developing treatments for rare diseases, building better batteries, and more. They’re chemical scientists at the top of their game. They’re role models building and mentoring teams. And yes, they’re badasses. They live by the motto “Nobody ever got anywhere by listening to no.”
By Ron Leuty – Staff Reporter, San Francisco Business Times
The company, called 4D Molecular Therapeutics Inc., doesn't expect to put its first three experimental single-shot cures for a range of diseases into clinical trials until next year. Yet it already has key partnerships with well-known drug makers Roche, AstraZeneca plc and gene therapy pioneer uniQure NV. Founders David Schaffer, The Hubbard Howe Jr. Distinguished Professor of Biochemical Engineering, and Dr. David Kirn have worked on so-called "viral vectors" — the protein shells ridden by viruses to skip through the body — since before the company was formed in 2013. In gene therapy, those vehicles are engineered to remove the disease-triggering part of a virus and used instead to carry correct versions of genes to replace mutated genes.
UCSF Department of Radiology & Biomedical Imaging press release
A research team from UCSF, UC Berkeley and 3D Printer Carbon, Inc. have created a drug sponge to absorb excess chemotherapy medication. The sponge is being designed so that after the chemotherapy has gone through the tumor, the part that hasn't treated the tumor could bind to the device, absorbing the excess dose like a "drug sponge." At the end of the procedure, the device is removed from the body, preventing the spread of toxicity throughout the body. "
Over the past 150 years, UC Berkeley has been at the forefront of scientific discovery, achieving milestones that have impacted both the research industry and the surrounding community.
Notable figures and facilities across campus have engaged in and continue to engage in progressing the scientific realm of society, whether it be founding modern statistical theory, producing plutonium...
A research team from UCSF, UC Berkeley and 3D Printer Carbon, Inc. have created a drug sponge to absorb excess chemotherapy medication. The sponge is being designed so that after the chemotherapy has gone through the tumor, the part that hasn't treated the tumor could bind to the device, absorbing the excess dose like a "drug sponge." At the end of the procedure, the device is removed from the body, preventing the spread of toxicity throughout the body. "
Over the past 150 years, UC Berkeley has been at the forefront of scientific discovery, achieving milestones that have impacted both the research industry and the surrounding community.
Dr. Ramelmeier discusses the future needs of talent in the biomanufacturing industry.